A Phase 1, First-in-human, Single-arm, Multi-center, Open-label, Repeated‑Dose, Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MP0274 in Patients With Advanced HER2-positive Solid Tumors

Trial Profile

A Phase 1, First-in-human, Single-arm, Multi-center, Open-label, Repeated‑Dose, Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MP0274 in Patients With Advanced HER2-positive Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs MP 0274 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Molecular Partners AG
  • Most Recent Events

    • 05 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 27 Oct 2016 According to Molecular Partners AG media release, first regulatory submission for phase 1 with MP0274 for the treatment of HER2-positive solid tumor has been planned for 1Q 2017.
    • 02 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top